APO Research
Talk to an analyst

APO RESEARCH · REPORT

Antiviral Drugs for Influenza

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Antiviral Drugs for Influenza Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

30 December 2025197 pages

Choose your research edition.

Industry ResearchAntiviral Drugs for Influenza Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Antiviral Drugs for Influenza Industry Growth and Trends Forecast to 2032109 pages · $3,450 USDMarket StructureGlobal Antiviral Drugs for Influenza Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Antiviral Drugs for Influenza Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Antiviral Drugs for Influenza Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Antiviral Drugs for Influenza market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Antiviral Drugs for Influenza is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Antiviral Drugs for Influenza is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Antiviral Drugs for Influenza is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Antiviral Drugs for Influenza is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Antiviral Drugs for Influenza include AdvaCare Pharma, Avexima, BioCryst Pharmaceuticals, Daiichi Sankyo, Morningside Pharmaceuticals, Shionogi, Wockhardt, GlaxoSmithKline and Roche, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Antiviral Drugs for Influenza market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Antiviral Drugs for Influenza and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Antiviral Drugs for Influenza sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Antiviral Drugs for Influenza market size, projected growth trends, production technologies, key applications, and end-use industries.

Antiviral Drugs for Influenza Segment by Company

AdvaCare Pharma

Avexima

BioCryst Pharmaceuticals

Daiichi Sankyo

Morningside Pharmaceuticals

Shionogi

Wockhardt

GlaxoSmithKline

Roche

Teva Pharmaceuticals

Antiviral Drugs for Influenza Segment by Type

Neuraminidase Inhibitors

Polymerase Inhibitors

Antiviral Drugs for Influenza Segment by Application

Over-the-counter (OTC)

Prescription (Rx)

Antiviral Drugs for Influenza Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Antiviral Drugs for Influenza market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Antiviral Drugs for Influenza and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Antiviral Drugs for Influenza.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Antiviral Drugs for Influenza market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Antiviral Drugs for Influenza manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Antiviral Drugs for Influenza in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Antiviral Drugs for Influenza in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Antiviral Drugs for Influenza Industry Trends Table 2. Antiviral Drugs for Influenza Industry Drivers Table 3. Antiviral Drugs for Influenza Industry Opportunities and Challenges Table 4. Antiviral Drugs for Influenza Industry Restraints Table 5. Global Antiviral Drugs for Influenza Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Antiviral Drugs for Influenza Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Antiviral Drugs for Influenza Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Antiviral Drugs for Influenza Sales Market Share by Manufacturers Table 9. Global Antiviral Drugs for Influenza Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Antiviral Drugs for Influenza Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Antiviral Drugs for Influenza Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Antiviral Drugs for Influenza Manufacturers, Product Type & Application Table 13. Global Antiviral Drugs for Influenza Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Antiviral Drugs for Influenza by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Neuraminidase Inhibitors Table 17. Major Manufacturers of Polymerase Inhibitors Table 18. Global Antiviral Drugs for Influenza Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Antiviral Drugs for Influenza Sales by Type (2021-2026) & (K Units) Table 20. Global Antiviral Drugs for Influenza Sales by Type (2027-2032) & (K Units) Table 21. Global Antiviral Drugs for Influenza Sales Market Share by Type (2021-2026) Table 22. Global Antiviral Drugs for Influenza Sales Market Share by Type (2027-2032) Table 23. Global Antiviral Drugs for Influenza Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Antiviral Drugs for Influenza Revenue by Type (2021-2026) & (K Units) Table 25. Global Antiviral Drugs for Influenza Revenue by Type (2027-2032) & (K Units) Table 26. Global Antiviral Drugs for Influenza Revenue Market Share by Type (2021-2026) Table 27. Global Antiviral Drugs for Influenza Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Over-the-counter (OTC) Table 29. Major Manufacturers of Prescription (Rx) Table 30. Global Antiviral Drugs for Influenza Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 31. Global Antiviral Drugs for Influenza Sales by Application (2021-2026) & (K Units) Table 32. Global Antiviral Drugs for Influenza Sales by Application (2027-2032) & (K Units) Table 33. Global Antiviral Drugs for Influenza Sales Market Share by Application (2021-2026) Table 34. Global Antiviral Drugs for Influenza Sales Market Share by Application (2027-2032) Table 35. Global Antiviral Drugs for Influenza Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 36. Global Antiviral Drugs for Influenza Revenue by Application (2021-2026) & (K Units) Table 37. Global Antiviral Drugs for Influenza Revenue by Application (2027-2032) & (K Units) Table 38. Global Antiviral Drugs for Influenza Revenue Market Share by Application (2021-2026) Table 39. Global Antiviral Drugs for Influenza Revenue Market Share by Application (2027-2032) Table 40. Global Antiviral Drugs for Influenza Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 41. Global Antiviral Drugs for Influenza Sales by Region (2021-2026) & (K Units) Table 42. Global Antiviral Drugs for Influenza Sales Market Share by Region (2021-2026) Table 43. Global Antiviral Drugs for Influenza Sales Forecasted by Region (2027-2032) & (K Units) Table 44. Global Antiviral Drugs for Influenza Sales Forecasted Market Share by Region (2027-2032) Table 45. North America Antiviral Drugs for Influenza Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 46. North America Antiviral Drugs for Influenza Sales by Country (2021-2026) & (K Units) Table 47. North America Antiviral Drugs for Influenza Sales by Country (2027-2032) & (K Units) Table 48. Europe Antiviral Drugs for Influenza Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. Europe Antiviral Drugs for Influenza Sales by Country (2021-2026) & (K Units) Table 50. Europe Antiviral Drugs for Influenza Sales by Country (2027-2032) & (K Units) Table 51. Asia Pacific Antiviral Drugs for Influenza Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Asia Pacific Antiviral Drugs for Influenza Sales by Country (2021-2026) & (K Units) Table 53. Asia Pacific Antiviral Drugs for Influenza Sales by Country (2027-2032) & (K Units) Table 54. South America, Middle East and Africa Antiviral Drugs for Influenza Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. South America, Middle East and Africa Antiviral Drugs for Influenza Sales by Country (2021-2026) & (K Units) Table 56. South America, Middle East and Africa Antiviral Drugs for Influenza Sales by Country (2027-2032) & (K Units) Table 57. Global Antiviral Drugs for Influenza Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 58. Global Antiviral Drugs for Influenza Revenue by Region (2021-2026) & (US$ Million) Table 59. Global Antiviral Drugs for Influenza Revenue by Region (2027-2032) & (US$ Million) Table 60. Global Antiviral Drugs for Influenza Revenue Market Share by Region (2021-2026) Table 61. Global Antiviral Drugs for Influenza Revenue Market Share by Region (2027-2032) Table 62. AdvaCare Pharma Company Information Table 63. AdvaCare Pharma Business Overview Table 64. AdvaCare Pharma Antiviral Drugs for Influenza Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. AdvaCare Pharma Antiviral Drugs for Influenza Product Portfolio Table 66. AdvaCare Pharma Recent Development Table 67. Avexima Company Information Table 68. Avexima Business Overview Table 69. Avexima Antiviral Drugs for Influenza Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Avexima Antiviral Drugs for Influenza Product Portfolio Table 71. Avexima Recent Development Table 72. BioCryst Pharmaceuticals Company Information Table 73. BioCryst Pharmaceuticals Business Overview Table 74. BioCryst Pharmaceuticals Antiviral Drugs for Influenza Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. BioCryst Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio Table 76. BioCryst Pharmaceuticals Recent Development Table 77. Daiichi Sankyo Company Information Table 78. Daiichi Sankyo Business Overview Table 79. Daiichi Sankyo Antiviral Drugs for Influenza Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Daiichi Sankyo Antiviral Drugs for Influenza Product Portfolio Table 81. Daiichi Sankyo Recent Development Table 82. Morningside Pharmaceuticals Company Information Table 83. Morningside Pharmaceuticals Business Overview Table 84. Morningside Pharmaceuticals Antiviral Drugs for Influenza Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Morningside Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio Table 86. Morningside Pharmaceuticals Recent Development Table 87. Shionogi Company Information Table 88. Shionogi Business Overview Table 89. Shionogi Antiviral Drugs for Influenza Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. Shionogi Antiviral Drugs for Influenza Product Portfolio Table 91. Shionogi Recent Development Table 92. Wockhardt Company Information Table 93. Wockhardt Business Overview Table 94. Wockhardt Antiviral Drugs for Influenza Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 95. Wockhardt Antiviral Drugs for Influenza Product Portfolio Table 96. Wockhardt Recent Development Table 97. GlaxoSmithKline Company Information Table 98. GlaxoSmithKline Business Overview Table 99. GlaxoSmithKline Antiviral Drugs for Influenza Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 100. GlaxoSmithKline Antiviral Drugs for Influenza Product Portfolio Table 101. GlaxoSmithKline Recent Development Table 102. Roche Company Information Table 103. Roche Business Overview Table 104. Roche Antiviral Drugs for Influenza Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 105. Roche Antiviral Drugs for Influenza Product Portfolio Table 106. Roche Recent Development Table 107. Teva Pharmaceuticals Company Information Table 108. Teva Pharmaceuticals Business Overview Table 109. Teva Pharmaceuticals Antiviral Drugs for Influenza Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 110. Teva Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio Table 111. Teva Pharmaceuticals Recent Development Table 112. Key Raw Materials Table 113. Raw Materials Key Suppliers Table 114. Antiviral Drugs for Influenza Distributors List Table 115. Antiviral Drugs for Influenza Customers List Table 116. Research Programs/Design for This Report Table 117. Authors List of This Report Table 118. Secondary Sources Table 119. Primary Sources List of Figures Figure 1. Antiviral Drugs for Influenza Product Image Figure 2. Global Antiviral Drugs for Influenza Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Antiviral Drugs for Influenza Market Size (2021-2032) & (US$ Million) Figure 4. Global Antiviral Drugs for Influenza Sales (2021-2032) & (K Units) Figure 5. Global Antiviral Drugs for Influenza Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Antiviral Drugs for Influenza Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Neuraminidase Inhibitors Image Figure 9. Polymerase Inhibitors Image Figure 10. Global Antiviral Drugs for Influenza Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Antiviral Drugs for Influenza Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Antiviral Drugs for Influenza Sales Market Share by Type (2021-2032) Figure 13. Global Antiviral Drugs for Influenza Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Antiviral Drugs for Influenza Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Antiviral Drugs for Influenza Revenue Market Share by Type (2021-2032) Figure 16. Over-the-counter (OTC) Image Figure 17. Prescription (Rx) Image Figure 18. Global Antiviral Drugs for Influenza Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 19. Global Antiviral Drugs for Influenza Sales Market Share 2021 VS 2025 VS 2032 Figure 20. Global Antiviral Drugs for Influenza Sales Market Share by Application (2021-2032) Figure 21. Global Antiviral Drugs for Influenza Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Antiviral Drugs for Influenza Revenue Market Share 2021 VS 2025 VS 2032 Figure 23. Global Antiviral Drugs for Influenza Revenue Market Share by Application (2021-2032) Figure 24. North America Antiviral Drugs for Influenza Sales and Growth Rate (2021-2032) & (K Units) Figure 25. North America Antiviral Drugs for Influenza Sales Market Share by Country (2021-2032) Figure 26. U.S. Antiviral Drugs for Influenza Sales and Growth Rate (2021-2032) & (K Units) Figure 27. Canada Antiviral Drugs for Influenza Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Mexico Antiviral Drugs for Influenza Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Europe Antiviral Drugs for Influenza Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Antiviral Drugs for Influenza Sales Market Share by Country (2021-2032) Figure 31. Germany Antiviral Drugs for Influenza Sales and Growth Rate (2021-2032) & (K Units) Figure 32. France Antiviral Drugs for Influenza Sales and Growth Rate (2021-2032) & (K Units) Figure 33. U.K. Antiviral Drugs for Influenza Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Italy Antiviral Drugs for Influenza Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Netherlands Antiviral Drugs for Influenza Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Asia Pacific Antiviral Drugs for Influenza Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Antiviral Drugs for Influenza Sales Market Share by Country (2021-2032) Figure 38. China Antiviral Drugs for Influenza Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Japan Antiviral Drugs for Influenza Sales and Growth Rate (2021-2032) & (K Units) Figure 40. South Korea Antiviral Drugs for Influenza Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Southeast Asia Antiviral Drugs for Influenza Sales and Growth Rate (2021-2032) & (K Units) Figure 42. India Antiviral Drugs for Influenza Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Australia Antiviral Drugs for Influenza Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South America, Middle East and Africa Antiviral Drugs for Influenza Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Antiviral Drugs for Influenza Sales Market Share by Country (2021-2032) Figure 46. Brazil Antiviral Drugs for Influenza Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South Africa Antiviral Drugs for Influenza Sales and Growth Rate (2021-2032) & (K Units) Figure 48. Saudi Arabia Antiviral Drugs for Influenza Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Turkey Antiviral Drugs for Influenza Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Argentina Antiviral Drugs for Influenza Sales and Growth Rate (2021-2032) & (K Units) Figure 51. UAE Antiviral Drugs for Influenza Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Egypt Antiviral Drugs for Influenza Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Chile Antiviral Drugs for Influenza Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Global Antiviral Drugs for Influenza Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Global Antiviral Drugs for Influenza Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 56. North America Antiviral Drugs for Influenza Revenue (2021-2032) & (US$ Million) Figure 57. North America Antiviral Drugs for Influenza Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 58. Europe Antiviral Drugs for Influenza Revenue (2021-2032) & (US$ Million) Figure 59. Europe Antiviral Drugs for Influenza Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Asia-Pacific Antiviral Drugs for Influenza Revenue (2021-2032) & (US$ Million) Figure 61. Asia-Pacific Antiviral Drugs for Influenza Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. South America, Middle East and Africa Antiviral Drugs for Influenza Revenue (2021-2032) & (US$ Million) Figure 63. South America, Middle East and Africa Antiviral Drugs for Influenza Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Antiviral Drugs for Influenza Value Chain Figure 65. Manufacturing Cost Structure Figure 66. Antiviral Drugs for Influenza Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Neuraminidase Inhibitors
  • Polymerase Inhibitors
Applications
  • Over-the-counter (OTC)
  • Prescription (Rx)
Companies covered
  • AdvaCare Pharma
  • Avexima
  • BioCryst Pharmaceuticals
  • Daiichi Sankyo
  • Morningside Pharmaceuticals
  • Shionogi
  • Wockhardt
  • GlaxoSmithKline
  • Roche
  • Teva Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Antiviral Drugs for Influenza Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Antiviral Drugs for Influenza Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Antiviral Drugs for Influenza Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Antiviral Drugs for Influenza Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Antiviral Drugs for Influenza Market Dynamics
  1. 2.1 Antiviral Drugs for Influenza Industry Trends
  2. 2.2 Antiviral Drugs for Influenza Industry Drivers
  3. 2.3 Antiviral Drugs for Influenza Industry Opportunities and Challenges
  4. 2.4 Antiviral Drugs for Influenza Industry Restraints
3 Antiviral Drugs for Influenza Market by Manufacturers
  1. 3.1 Global Antiviral Drugs for Influenza Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Antiviral Drugs for Influenza Sales by Manufacturers (2021-2026)
  3. 3.3 Global Antiviral Drugs for Influenza Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Antiviral Drugs for Influenza Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Antiviral Drugs for Influenza Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Antiviral Drugs for Influenza Manufacturers, Product Type & Application
  7. 3.7 Global Antiviral Drugs for Influenza Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Antiviral Drugs for Influenza Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Antiviral Drugs for Influenza Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Antiviral Drugs for Influenza Tier 1, Tier 2, and Tier 3
4 Antiviral Drugs for Influenza Market by Type
  1. 4.1 Antiviral Drugs for Influenza Type Introduction
  2. 4.1.1 Neuraminidase Inhibitors
  3. 4.1.2 Polymerase Inhibitors
  4. 4.2 Global Antiviral Drugs for Influenza Sales by Type
  5. 4.2.1 Global Antiviral Drugs for Influenza Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Antiviral Drugs for Influenza Sales by Type (2021-2032)
  7. 4.2.3 Global Antiviral Drugs for Influenza Sales Market Share by Type (2021-2032)
  8. 4.3 Global Antiviral Drugs for Influenza Revenue by Type
  9. 4.3.1 Global Antiviral Drugs for Influenza Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Antiviral Drugs for Influenza Revenue by Type (2021-2032)
  11. 4.3.3 Global Antiviral Drugs for Influenza Revenue Market Share by Type (2021-2032)
5 Antiviral Drugs for Influenza Market by Application
  1. 5.1 Antiviral Drugs for Influenza Application Introduction
  2. 5.1.1 Over-the-counter (OTC)
  3. 5.1.2 Prescription (Rx)
  4. 5.2 Global Antiviral Drugs for Influenza Sales by Application
  5. 5.2.1 Global Antiviral Drugs for Influenza Sales by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Antiviral Drugs for Influenza Sales by Application (2021-2032)
  7. 5.2.3 Global Antiviral Drugs for Influenza Sales Market Share by Application (2021-2032)
  8. 5.3 Global Antiviral Drugs for Influenza Revenue by Application
  9. 5.3.1 Global Antiviral Drugs for Influenza Revenue by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Antiviral Drugs for Influenza Revenue by Application (2021-2032)
  11. 5.3.3 Global Antiviral Drugs for Influenza Revenue Market Share by Application (2021-2032)
6 Global Antiviral Drugs for Influenza Sales by Region
  1. 6.1 Global Antiviral Drugs for Influenza Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Antiviral Drugs for Influenza Sales by Region (2021-2032)
  3. 6.2.1 Global Antiviral Drugs for Influenza Sales by Region (2021-2026)
  4. 6.2.2 Global Antiviral Drugs for Influenza Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Antiviral Drugs for Influenza Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Antiviral Drugs for Influenza Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Antiviral Drugs for Influenza Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Antiviral Drugs for Influenza Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Antiviral Drugs for Influenza Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Antiviral Drugs for Influenza Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Antiviral Drugs for Influenza Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Antiviral Drugs for Influenza Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Antiviral Drugs for Influenza Revenue by Region
  1. 7.1 Global Antiviral Drugs for Influenza Revenue by Region
  2. 7.1.1 Global Antiviral Drugs for Influenza Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Antiviral Drugs for Influenza Revenue by Region (2021-2026)
  4. 7.1.3 Global Antiviral Drugs for Influenza Revenue by Region (2027-2032)
  5. 7.1.4 Global Antiviral Drugs for Influenza Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Antiviral Drugs for Influenza Revenue (2021-2032)
  8. 7.2.2 North America Antiviral Drugs for Influenza Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Antiviral Drugs for Influenza Revenue (2021-2032)
  11. 7.3.2 Europe Antiviral Drugs for Influenza Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Antiviral Drugs for Influenza Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Antiviral Drugs for Influenza Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Antiviral Drugs for Influenza Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Antiviral Drugs for Influenza Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 AdvaCare Pharma
  2. 8.1.1 AdvaCare Pharma Company Information
  3. 8.1.2 AdvaCare Pharma Business Overview
  4. 8.1.3 AdvaCare Pharma Antiviral Drugs for Influenza Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AdvaCare Pharma Antiviral Drugs for Influenza Product Portfolio
  6. 8.1.5 AdvaCare Pharma Recent Developments
  7. 8.2 Avexima
  8. 8.2.1 Avexima Company Information
  9. 8.2.2 Avexima Business Overview
  10. 8.2.3 Avexima Antiviral Drugs for Influenza Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Avexima Antiviral Drugs for Influenza Product Portfolio
  12. 8.2.5 Avexima Recent Developments
  13. 8.3 BioCryst Pharmaceuticals
  14. 8.3.1 BioCryst Pharmaceuticals Company Information
  15. 8.3.2 BioCryst Pharmaceuticals Business Overview
  16. 8.3.3 BioCryst Pharmaceuticals Antiviral Drugs for Influenza Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 BioCryst Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio
  18. 8.3.5 BioCryst Pharmaceuticals Recent Developments
  19. 8.4 Daiichi Sankyo
  20. 8.4.1 Daiichi Sankyo Company Information
  21. 8.4.2 Daiichi Sankyo Business Overview
  22. 8.4.3 Daiichi Sankyo Antiviral Drugs for Influenza Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Daiichi Sankyo Antiviral Drugs for Influenza Product Portfolio
  24. 8.4.5 Daiichi Sankyo Recent Developments
  25. 8.5 Morningside Pharmaceuticals
  26. 8.5.1 Morningside Pharmaceuticals Company Information
  27. 8.5.2 Morningside Pharmaceuticals Business Overview
  28. 8.5.3 Morningside Pharmaceuticals Antiviral Drugs for Influenza Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Morningside Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio
  30. 8.5.5 Morningside Pharmaceuticals Recent Developments
  31. 8.6 Shionogi
  32. 8.6.1 Shionogi Company Information
  33. 8.6.2 Shionogi Business Overview
  34. 8.6.3 Shionogi Antiviral Drugs for Influenza Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Shionogi Antiviral Drugs for Influenza Product Portfolio
  36. 8.6.5 Shionogi Recent Developments
  37. 8.7 Wockhardt
  38. 8.7.1 Wockhardt Company Information
  39. 8.7.2 Wockhardt Business Overview
  40. 8.7.3 Wockhardt Antiviral Drugs for Influenza Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Wockhardt Antiviral Drugs for Influenza Product Portfolio
  42. 8.7.5 Wockhardt Recent Developments
  43. 8.8 GlaxoSmithKline
  44. 8.8.1 GlaxoSmithKline Company Information
  45. 8.8.2 GlaxoSmithKline Business Overview
  46. 8.8.3 GlaxoSmithKline Antiviral Drugs for Influenza Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 GlaxoSmithKline Antiviral Drugs for Influenza Product Portfolio
  48. 8.8.5 GlaxoSmithKline Recent Developments
  49. 8.9 Roche
  50. 8.9.1 Roche Company Information
  51. 8.9.2 Roche Business Overview
  52. 8.9.3 Roche Antiviral Drugs for Influenza Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Roche Antiviral Drugs for Influenza Product Portfolio
  54. 8.9.5 Roche Recent Developments
  55. 8.10 Teva Pharmaceuticals
  56. 8.10.1 Teva Pharmaceuticals Company Information
  57. 8.10.2 Teva Pharmaceuticals Business Overview
  58. 8.10.3 Teva Pharmaceuticals Antiviral Drugs for Influenza Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Teva Pharmaceuticals Antiviral Drugs for Influenza Product Portfolio
  60. 8.10.5 Teva Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Antiviral Drugs for Influenza Value Chain Analysis
  2. 9.1.1 Antiviral Drugs for Influenza Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Antiviral Drugs for Influenza Production Mode & Process
  6. 9.2 Antiviral Drugs for Influenza Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Antiviral Drugs for Influenza Distributors
  9. 9.2.3 Antiviral Drugs for Influenza Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst